IL-12 and neutralization of endogenous IL-10 revert the in vitro antigen-specific cellular immunosuppression of paracoccidioidomycosis patients

Página do item simplificado
dc.contributor.authorRomano, Carla C.
dc.contributor.authorMendes-Giannini, Maria José Soares [UNESP]
dc.contributor.authorDuarte, Alberto J.S.
dc.contributor.authorBenard, Gil
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-27T11:20:29Z
dc.date.available2014-05-27T11:20:29Z
dc.date.issued2002-07-25
dc.description.abstractTreatment of patients with paracoccidioidomycosis is still a challenge. Patients present defective lymphoproliferation and IFN-γ responses to the main Paracoccidioides brasiliensis antigen (gp43), which correlates with disease severity. Here, we demonstrated that the patients show also a defective synthesis of interleukin (IL)-12. Therefore, we attempted to revert this immune disfunction by adding IL-12 and neutralizing anti-IL-10 antibody to gp-43-stimulated peripheral blood mononuclear cell cultures. Both treatments increased IFN-γ secretion to levels observed with healthy sensitized individuals, but affected proliferation only modestly. When combined, the treatments further increased IFN-γ synthesis and cell proliferation. The addition of suboptimal concentrations of IL-2 also further increased the IL-12-mediated secretion of IFN-γ. Interestingly, the immune modulation was mostly antigen-specific, since the responses to Candida albicans' antigen were not affected. These results suggest that appropriate immune intervention with cytokines and/or anti-cytokines may help in the treatment of PCM. © 2002 Elsevier Science Ltd. All rights reserved.en
dc.description.affiliationLaboratório de Alergia E Imunologia Clínica E Experimental LIM 56 Faculdade de Medicina Universidade de São Paulo
dc.description.affiliationDepartamento de Análises Clínicas Da Faculdade de Ciências Farmacêuticas UNESP, Araraquara
dc.description.affiliationClínica de Doenças Infecciosas E Parasitárias Hospital Das Clínicas Da FMUSP, São Paulo
dc.description.affiliationUnespDepartamento de Análises Clínicas Da Faculdade de Ciências Farmacêuticas UNESP, Araraquara
dc.format.extent149-157
dc.identifierhttp://dx.doi.org/10.1006/cyto.2002.0884
dc.identifier.citationCytokine, v. 18, n. 3, p. 149-157, 2002.
dc.identifier.doi10.1006/cyto.2002.0884
dc.identifier.issn1043-4666
dc.identifier.orcid0000-0002-8059-0826
dc.identifier.scopus2-s2.0-0035997261
dc.identifier.urihttp://hdl.handle.net/11449/66938
dc.identifier.wosWOS:000177591000005
dc.language.isoeng
dc.relation.ispartofCytokine
dc.relation.ispartofjcr3.514
dc.relation.ispartofsjr1,433
dc.rights.accessRightsAcesso restrito
dc.sourceScopus
dc.subjectInterleukin-10
dc.subjectInterleukin-12
dc.subjectParacoccidioides brasiliensis
dc.subjectParacoccidioidomycosis
dc.subjectgamma interferon
dc.subjectglycoprotein
dc.subjectglycoprotein gp 43
dc.subjectinterleukin 10
dc.subjectinterleukin 12
dc.subjectinterleukin 2
dc.subjectneutralizing antibody
dc.subjectunclassified drug
dc.subject43 kDa protein, Paracoccidioides
dc.subjectfungal protein
dc.subjectfungus antigen
dc.subjectoligosaccharide
dc.subjectadolescent
dc.subjectadult
dc.subjectaged
dc.subjectcell proliferation
dc.subjectcell stimulation
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectcytokine production
dc.subjectcytokine release
dc.subjecthuman
dc.subjectimmune deficiency
dc.subjectimmune response
dc.subjectimmunomodulation
dc.subjectlymphocyte proliferation
dc.subjectmononuclear cell
dc.subjectpriority journal
dc.subjectschool child
dc.subjectSouth American blastomycosis
dc.subjectbiosynthesis
dc.subjectchild
dc.subjectdrug antagonism
dc.subjectdrug effect
dc.subjectimmunological tolerance
dc.subjectimmunology
dc.subjectin vitro study
dc.subjectlymphocyte activation
dc.subjectmiddle aged
dc.subjectParacoccidioides
dc.subjectserodiagnosis
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAntigens, Fungal
dc.subjectChild
dc.subjectGlycoproteins
dc.subjectHuman
dc.subjectImmune Tolerance
dc.subjectIn Vitro
dc.subjectInterferon Type II
dc.subjectLymphocyte Activation
dc.subjectMiddle Age
dc.subjectNeutralization Tests
dc.subjectOligosaccharides
dc.subjectSupport, Non-U.S. Gov't
dc.subjectFungal Proteins
dc.subjectHumans
dc.subjectMiddle Aged
dc.subjectCandida
dc.subjectCandida albicans
dc.titleIL-12 and neutralization of endogenous IL-10 revert the in vitro antigen-specific cellular immunosuppression of paracoccidioidomycosis patientsen
dc.typeArtigo
dcterms.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
unesp.author.orcid0000-0002-8059-0826[2]
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Ciências Farmacêuticas, Araraquarapt

Arquivos

Coleções

Artigos - Análises Clínicas - FCFAR